Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini - LARVOL DELTA

Resistance development to new anti-gram negatives during treatment: geographical epidemiology and risk factors. (PubMed, Clin Microbiol Infect) - "Treatment-emergent resistance is a consequence of antibiotic exposure, but its impact is likely underestimated. Preventive strategies include optimization of pharmacokinetic/pharmacodynamic targets, therapeutic drug monitoring, timely and complete source control, and stewardship-driven rational use of novel agents."

Journal • Review • Infectious Disease

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. (PubMed, J Antimicrob Chemother) - "Our findings underscore the need to take this phenotype into account in clinical practice and confirm the limited activity of conventional β-lactams against AmpC-hyperproducing E. cloacae complex and K. aerogenes, and support the use of newer agents as effective alternatives."

Clinical • Journal

Preserving the Antimycobacterial Drug Arsenal: A Case Report of Disseminated Mycobacterium Avium Disease (IWLH 2026) - "The patient was treated with clarithromycin, ethambutol, rifabutin, moxifloxacin, and cycloserine for two years, with amikacin added for the first six months, inducing ototoxicity...A salvage regimen was initiated, including amikacin, tedizolid, clofazimine, ceftazidime/avibactam, isoniazid, delamanide, and ethambutol, as well as antiepileptic treatment and IFNγ administration...Intravenous dexamethasone was administered with intensified NTM treatment, but blood cell counts continued to decline, and inflammatory markers (CRP, PCT) remained high. Due to previous Gram-negative infections, his regimen was modified to include daptomycin, meropenem/vaborbactam, and colistimethate. Candida glabrata was identified in port cultures, necessitating port removal and initiation of isavuconazole. He was placed on dual beta-lactam therapy (meropenem and ceftriaxone) combined with clofazimine, isoniazid, linezolid, cycloserine, bedaquiline, and pretomanid...Conclusions This case..."

Case report • Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • IFNG • IL12A

Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion. (PubMed, Pharmaceutics) - " The aim of this study was to develop and validate two rapid, sensitive, and accurate UPLC-qTOF-MS/MS methods for the simultaneous quantification of five novel β-lactam or β-lactam/β-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, cefiderocol, and ceftobiprole) along with fosfomycin. These UPLC-qTOF-MS/MS multi-analyte methods enabled a simultaneous, reliable quantification in plasma of five novel beta-lactams and of fosfomycin. Robustness, high throughput, and sensitivity make these multi-methods feasible for real-time TDM, supporting personalized antimicrobial dosing and improved therapeutic outcomes in patients with severe or multidrug-resistant infections."

Journal • Infectious Disease

Development of a rapid susceptibility testing system for cefiderocol, aztreonam/avibactam, ceftolozane/tazobactam and meropenem/vaborbactam directly from positive blood cultures (ESCMID Global 2026) - No abstract available

Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. (PubMed, Front Microbiol) - "This review systematically summarizes the molecular resistance mechanisms that World Health Organization (WHO) priority bacterial pathogens have already deployed against the 15 new antibiotics approved between 2017 and 2025, including β-lactam/β-lactamase inhibitors (cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam), tetracycline derivatives (eravacycline, omadacycline), a pleuromutilin (lefamulin), an aminoglycoside (plazomicin), and a fluoroquinolone (delafloxacin). Preserving the efficacy of these essential drugs thus necessitates a multifaceted, globally coordinated "One Health" strategy. Finally, we discuss how the growing complexity of AMR mechanisms is driving the need for advanced diagnostic tools, exploring the pivotal role of bioinformatics and artificial intelligence in predicting resistance and closing knowledge gaps."

Journal • Review

Efficacy of meropenem/vaborbactam against planktonic and biofilm forms of KPC-producing carbapenem-resistant Klebsiella pneumoniae (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pneumonia

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam (ESCMID Global 2026) - No abstract available

Comparative effectiveness of ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam for multidrug-resistant Gram-negative bloodstream infections: a retrospective cohort study (ESCMID Global 2026) - No abstract available

Gram negative • HEOR • Retrospective data • Infectious Disease

Trends in meropenem/vaborbactam minimum inhibitory concentrations against kpc-producing uropathogens: three-year analysis (ESCMID Global 2026) - No abstract available

Deciphering resistance development under in vitro meropenem/vaborbactam or imipenem/relebactam exposure in KPC-producing Klebsiella pneumoniae ST307 high-risk clone (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Impact of aggressive joint PK/PD target attainment of CI meropenem/vaborbactam monotherapy on the microbiological outcome of documented KPC-producing Enterobacterales infections (ESCMID Global 2026) - No abstract available

Monotherapy • PK/PD data • Infectious Disease

Meropenem/vaborbactam distribution in the human renal and prostatic interstitium tissues in rats and pigs using microdialysis (ESCMID Global 2026) - No abstract available

Preclinical

IS28 - Saving the vulnerable: innovative strategies against AMR in high-risk hosts (ESCMID Global 2026) - "The challenges of diagnosing and initiating appropriate and effective early antibiotic treatment need a personalized tailored approach to improve patient?s care. The session will focus on the burden of AMR in high-risk populations (oncology, transplant, ICU), highlighting clinical data supporting meropenem-vaborbactam as a first line agent in the treatment of CRE-KPC non-OXA48 MDR infections in these populations."

Infectious Disease • Solid Organ Transplantation

New antimicrobial substances to combat increasing resistance (PubMed, Inn Med (Heidelb)) - "In addition to cefiderocol, the first siderophore cephalosporin, new combinations of β‑lactam antibiotics and β‑lactamase inhibitors (BLIs) such as ceftolozan/tazobactam, ceftazidime/avibactam, cefepime/enmetazobactam, imipenem/cilastatin/relebactam, and meropenem/vaborbactam, as well as the monobactam/BLI combination aztreonam/avibactam, have been approved and successfully implemented in clinical care. In addition, there is the synthetic tetracycline antibiotic eravacycline, which has a broad spectrum of activity against Gram-positive, Gram-negative (particularly clinically relevant Enterobacterales), anaerobic, and multidrug-resistant bacteria, and the new glycopeptide antibiotic dalbavancin, which is effective against Gram-positive bacteria...Some of these agents have already been tested with promising results in smaller phase 1/2 studies. In addition, monoclonal antibodies, antimicrobial peptides, small molecules, microbiome-modifying biotherapeutics,..."

Journal • Review • Infectious Disease

Discharge Delays and Costs Associated With Outpatient Parenteral Antimicrobial Therapy for Multidrug-Resistant Organisms: A Retrospective Cohort Study. (PubMed, Open Forum Infect Dis) - "This was an institutional review board-approved, retrospective cohort of hospitalized, MDRO-infected adults medically stable for discharge (MSDC) with an intended OPAT for cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, eravacycline, meropenem/vaborbactam, or tigecycline from 1 January 2017 through 31 March 2025. Modified OPAT regimens are common and associated with increased costs, prolonged LOS, and discharge delays in MDRO-infected patients. These findings support the use of oral-switch therapy and improved care coordination."

Journal • Retrospective data

Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. (PubMed, Antimicrob Agents Chemother) - "M/V showed no statistically significant difference over C/A; therefore, selection should be guided judiciously based on clinical context. Further studies are needed to define the optimal role of each agent within antimicrobial stewardship frameworks."

Journal • Retrospective data • Infectious Disease • Respiratory Diseases

Recent Advancements in the Diversification and Applications of Boron-Containing Compounds in Medicinal Chemistry. (PubMed, Pharmaceuticals (Basel)) - "Boron-containing compounds have made a significant impact on the field of medicinal chemistry since the discovery of Bortezomib (Velcade®), a dipeptide boronic acid approved by the FDA in 2003 for the treatment of multiple myeloma. Since then, over the last two decades, four more boron-containing drugs have been approved by the FDA: Tavaborole (Kerydin®), Ixazomib (Ninlaro®), Crisaborole (Eucrisa®), and Vaborbactam (in Vabomere®). These compounds are approved for treating conditions such as onychomycosis, multiple myeloma, and atopic dermatitis, as well as an Aβ-lactamase inhibitor approved in combination with meropenem for treating infections...This review aims to highlight the recent advances made in the last decade in the drug design of boron-containing compounds and their therapeutic applications. Here, in this work, we have focused on the recent diversification and progress of boron-containing compounds in medicinal chemistry applications."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Infectious Disease • Multiple Myeloma • Oncology

Multidrug-resistant gram-negative bacteria in Spanish ICU patients: clinical and microbiological characterization (MURAN-UCI Project). (PubMed, Microbiol Spectr) - "The antibiotics with the greatest activity against Enterobacterales (n = 26) were colistin, cefiderocol, and meropenem-vaborbactam (100%); while in CR P. aeruginosa (n = 20), they were colistin, cefiderocol, and imipenem-relebactam (95%-100%). We believe that monitoring resistance epidemiology at the ICU level-especially through molecular surveillance of resistance mechanisms and clonal dissemination-is essential for optimizing antimicrobial use and guiding stewardship and infection control programs. Notably, carbapenem-resistant Pseudomonas aeruginosa was the most frequently identified organism in both colonization (first/second week) and infection cases, highlighting the need for its inclusion in routine hospital colonization screening."

Journal • Critical care • Infectious Disease • Pneumonia

Emergence of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae: clinical and genomic insights from consecutive bloodstream infections. (PubMed, Infection) - "Resistance to novel BL/BLICs among KPC-producing K. pneumoniae is emerging in Italian hospitals, largely mediated by blaKPC variants and porin defects under selective antibiotic pressure. While ATM/AVI, MEM/VAB and IMP/REL remain highly active, resistance to CAZ/AVI is increasingly frequent. Continuous genomic surveillance and optimised antimicrobial stewardship are essential to preserve the efficacy of these last-line agents."

Journal • Infectious Disease • Pneumonia

The UK Antimicrobial Registry (UKAR): an overview of the first 20 months of recruitment. (PubMed, JAC Antimicrob Resist) - "UKAR is an ongoing prospective registry of adult inpatients prescribed 11 eligible study drugs (cefiderocol, ceftaroline, ceftazidime/avibactam, ceftobiprole, ceftolozane/tazobactam, dalbavancin, delafloxacin, eravacycline, imipenem/cilastatin/relebactam, meropenem/vaborbactam and oritavancin). The UKAR provides real-world data on the use of novel antimicrobials confirming they are sometimes used empirically as well as for directed therapy to treat both complex and common infections, and often for multiresistant pathogens. The study is a novel and important resource to support the judicious use of these drugs."

Journal • Critical care • Infectious Disease • Nephrology • Respiratory Diseases • Septic Shock

Therapeutic Drug Monitoring of Meropenem–Vaborbactam in a Pediatric Patient with Multidrug-Resistant Infections: A Case Report (ASHP 2025) - No abstract available

Case report • Clinical • Infectious Disease • Pediatrics

Sodium load of novel antibiotics: considerations for nephrologists and clinicians. (PubMed, Int Urol Nephrol) - "Parenteral antibiotics are an often-overlooked contributor to sodium intake. Clinicians should be aware of this hidden source in sodium-sensitive patients such as kidney disease patients. We propose a visual chart to support sodium-conscious antimicrobial selection as part of broader stewardship strategies."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease

Case Report of Treatment of Polymicrobial Bacteremia Caused by Carbapenem-Resistant Klebsiella pneumoniae, and Bacillus Species in an Immunocompetent Patient With Meropenem-Vaborbactam. (PubMed, J Pharm Pract) - "The Infectious Disease Society of America (IDSA) recommends meropenem-vaborbactam, ceftazidime-avibactam, or imipenem-cilastatin-relebactam as preferred options with cefiderocol as an alternative, all of which are also alternative options for CTX-M Enterobacterales...This case report illustrates the treatment course of CTX-M and KPC-producing Klebsiella pneumoniae, and Bacillus species bacteremia that included cefiderocol, followed by vancomycin and meropenem-vaborbactam, and then meropenem-vaborbactam monotherapy...In our report, an immunocompetent patient developed a polymicrobial bloodstream infection caused by an MDR Klebsiella pneumoniae, and Bacillus species, which was successfully treated with meropenem-vaborbactam. This unusual infection and treatment course also serves to promote awareness of another treatment option for invasive Bacillus species infection and furthermore encourages providers to request testing & sensitivities to consolidate therapy,..."

Journal • Infectious Disease • Pneumonia

Emergence of mutH V76G among longitudinal carbapenem resistant Klebsiella pneumoniae causing long-term colonization and recurrent infection disrupts DNA mismatch repair and results in a hypermutator phenotype. (PubMed, bioRxiv) - "Clinical mutH V76G isolates and CRISPR-engineered mutH V76G mutants were hypermutators based on rifampin mutational frequencies...Both clinical and lab-engineered mutH V76G mutant strains rapidly acquire resistance or reduced susceptibility to new antibiotics like ceftazidime-avibactam, meropenem-vaborbactam and cefiderocol, due to mutations in carbapenemase ( bla KPC-3 ), porin ( ompK36 ) and other genes. mutH V76G -driven hypermutation also enhances horizontal transfer of resistance plasmids and improves K. pneumoniae fitness during mouse infections. This study is important for understanding K. pneumoniae hypermutation as a potent mediator of antibiotic resistance and other phenotypes relevant to human infections."

Journal • Mismatch repair • Infectious Disease • Pneumonia